Kineret is an anti-inflammatory medicine that neutralises the biological activity of both cytokines IL-1α and β, which play a role in COVID19-induced hyperinflammation. Blocking these cytokines early in the course of the hyperinflammatory phase can have an important impact on COVID-19 disease progression, the company explained.
The FDA’s decision was based on positive results from the SAVE-MORE phase 3 trial which evaluated the safety and efficacy of a 100mg subcutaneous daily dose of Kineret for up to ten days.
